anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,132,933. Pharmaceutical compositions. DEUTSCHE GOLD-UND SILBERSCHEDEANSTALT. 1 June, 1967 [1 June, 1966; 15 March, 1967], No. 25345/67. Heading A5B. A solution comprises a fluorochloro hydrocarbon conventionally used as a propellant for aerosols, a pharmaceutical compound containing at least one basically reacting nitrogen atom, in a pharmacologically useful solvent or solvent mixture and a solution promoter comprising an aryl sulphonic acid optionally substituted by a C 1 -C 5  alkyl group, an alicyclic sulphonic acid optionally substituted by an alkyl group, a terpene sulphonic acid, camphor sulphonic acid or a sulphonic acid semiamide of the general formula in which R 1  and R 2  are the same or different and represent hydrogen atoms, phenyl or phenalkyl groups with 1-5 carbon atoms in the alkylene group or linear or branched C 1 -C 5  alkyl groups which may also be closed to form a ring optionally containing another oxygen or nitrogen atom. Many examples are given, including alkaloids, antibiotics, local anaesthetics and compounds having cardio-vascular sympathimomimetric and respiratory system activity.
OBJECTIVES: Confidence in long-term treatment results of radiofrequency ablation (RFA) for papillary thyroid microcarcinoma (PTMC) is required in comparison with surgery and active surveillance (AS). The objective of this meta-analysis is to report more than three years of follow-up results of radiofrequency ablation for PTMCs.
METHODS: Ovid PUBMED, COCHRANE, and EMBASE databases were searched through Nov 19, 2023, for studies reporting outcomes in patients with PTMC treated with radiofrequency ablation and followed up for more than 3 years. The standard mean difference of the tumor volume before and after therapy, tumor recurrence, lymph node (LN) metastasis, distant metastasis, complications, and the pooled volume reduction rates (VRRs) at 1, 3, 6, 12, 24, 36, and 48 months after radiofrequency ablation were assessed. Data were extracted and methodological quality was assessed independently by two radiologists according to the PRISMA guidelines.
RESULTS: Eight studies, involving 2131 patients, met the inclusion criteria through database searches. The overall VRR was 99.81 % (95 % CI: 99.68, 99.95) in the last follow-up. During a mean pooled follow-up of 46.59 months, 69 patients experienced local PTMC recurrence, with 8 cases within the ablation area. Additionally, 44 patients were diagnosed with newly discovered PTMC, and 17 patients exhibited lymph node metastases. Among the patients with PTMC recurrence, 3 were under active surveillance while 59 underwent additional RFA. The pooled mean complication rate was 2.80 %, with no instances of life-threatening or delayed complications.
CONCLUSIONS: Radiofrequency ablation proves to be an effective local tumor control method for low-risk PTMC patients, resulting in clinically significant and enduring volume reduction. The rate of regrowth and retreatment requirement post-RFA was notably lower, positioning RFA as a compelling alternative to existing treatment options.
Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. 

In randomized controlled trials of treatment-naive patients, clinical lipoatrophy or lipodystrophy developed in a higher proportion of patients treated with stavudine compared to other nucleosides (tenofovir or abacavir). Dual energy x-ray absorptiometry (DEXA) scans demonstrated overall limb fat loss in stavudine-treated patients compared to limb fat gain or no gain in patients treated with other nucleosides (abacavir, tenofovir or zidovudine). The incidence and severity of lipoatrophy or lipodystrophy are cumulative over time with stavudine-containing regimens. In clinical trials, switching from stavudine to other nucleosides (tenofovir or abacavir) resulted in increases in limb fat with modest to no improvements in clinical lipoatrophy. Patients receiving stavudine should be monitored for symptoms or signs of lipoatrophy or lipodystrophy and questioned about body changes related to lipoatrophy or lipodystrophy. Given the potential risks of using stavudine including lipoatrophy or lipodystrophy, a benefit-risk assessment for each patient should be made and an alternative antiretroviral should be considered.
This is a single blinded, randomized clinical trial. Subjects will be male or female patients with Grade 1,2 or 3 OA of the knee classified based on the radiological Kellgren -Lawrence grading system.

100 patients will be recruited for this study and 50 patients each will be randomized to one of the treatment groups using block randomization i.e. receiving either treatment IA corticosteroids or IA PRP injections. The patients will be informed of and will be consented to the treatment they will be receiving. An investigator from the research team, blinded to group assignment, will assist patients in completing the Oxford Knee score, WOMAC and SF-12 scores prior to receiving the treatment and at 6 weeks, 3 months and 6 months after receiving the treatment. In addition, they will be followed by regularly (at 3 weeks, 9 weeks, 4 months and 5 months) via telephone to inquire about any side effects of the treatment and to document patient satisfaction. Subjects in both groups will continue to receive concomitant treatments both pharmacological and nonpharmacological. All subjects will receive physiotherapy sessions with their respective intervention. Subjects will continue to receive treatment even if they wish to withdraw from the study at any point.
Comatose survivors (GCS ≤8) after RoSC, in whom neurological prognosis is unknown at the time of admission. Neurological performance of patients from the study group (prospective and retrospective) will be categorized according to a risk score obtained from the multivariate spectral-based model.
Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. Previously, a germline pathogenic variant (GPV) in PHOX2B was associated with Hirschsprung disease and congenital central hypoventilation syndrome. Recently, certain GPVs were shown to be responsible for congenital central hypoventilation syndrome and NB predisposition. Also, several groups determined that activating GPVs in ALK accounted for a substantial number of familial NB. Finally, there are additional genes and cancer predisposition syndromes in which NB occurs with greater frequency or that have been associated with NB based on genome-wide association studies. We review the evidence for all these genes and whether there is sufficient evidence to warrant surveillance. We review recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017.
Low dose: Participants randomized to the low dose group will receive 0.5 mg of buprenorphine/naloxone on day 1, 0.5 mg bid on day 2, 1.0 mg bid on day 3, 2.0 mg bid on day 4, 4.0 mg bid on day 5, 4.0 mg tid on day 6, and 8 mg bid on day 7. Thereafter, dosing adjustments can be made in the first three months of the trial.
PURPOSE:To efficiently obtain the subject substance useful as a hepatitis C vaccine, for diagnosis, etc., by transforming a host with an expression vector containing a DNA fragment capable of coding a coat protein of hepatitis C virus, culturing the resultant transformant and then collecting the extracellularly produced substance. CONSTITUTION:A 50mM tris buffer solution is added to a blood serum of a patient suffering from hepatitis C and the resultant mixture is centrifuged at 20 deg.C for 20min. The obtained supernatant is ultracentrifuged for 5hr and Protenase K(R) and sodium dodecyl sulfate are then added to the formed precipitate to carry out the lysis. The lysate is subsequently extracted with phenol/chloroform to recover nucleic acid, which is then used to synthesize a cDNA. The synthesized cDNA is treated with a restriction enzyme and bound to a vector. The resultant DNA is used to transform Escherichia coli. The transformed Escherichia coli is cloned to sort out a positive clone and its plasmid is recovered, treated with a restriction enzyme and bound to an expression vector. A host is transformed with the resultant expression vector containing a DNA fragment capable of coding a coat protein of the hepatitis C virus and cultured to obtain an extracellularly produced substance. Thereby, the objective coat protein of the hepatitis virus C is provided.
All women in the experimental group receive standardized high-intensity interval training over a period of 6 months in combination with neoadjuvant therapy (immunochemotherapy). The individual training sessions are guided and monitored by qualified exercise therapists, taking into account the side effects of ongoing treatment. Each training session will last about one hour, with the effective training time being 30 minutes. Bike training begins 1 hour before neoadjuvant therapy and then at the same time of day between therapies. The TNBC patients start with 5 minutes of cycling followed by 3 × 3 - minute HIIT training sequences, constantly alternating: i) 30 s at 90% of maximal PO (70 rpm for 30 s) and ii) 30 s of light pedaling at 20% of PO). The training session will be concluded with a 5-min cool-down cycling (easy pedaling) and stretching. This protocol will be performed twice a week throughout the study.
BACKGROUND: Ventilator-associated pneumonia (VAP) is one of the leading causes of mortality in patients with critical care illness. Since obesity is highly prevalent, we wanted to study its impact on the outcomes of patients who develop VAP.
METHODS: Using the National Inpatient Sample (NIS) database from 2017 to 2020, we conducted a retrospective study of adult patients with a principal diagnosis of VAP with a secondary diagnosis with or without obesity according to 10th revision of the International Statistical Classification of Diseases (ICD-10) codes. Several demographics, including age, race, and gender, were analyzed. The primary endpoint was mortality, while the secondary endpoints included tracheostomy, length of stay in days, and patient charge in dollars. Multivariate logistic regression model analysis was used to adjust for confounders, with a p-value less than 0.05 considered statistically significant.
RESULTS: The study included 3832 patients with VAP, 395 of whom had obesity. The mean age in both groups was around 58 years, and 68% of the group with obesity were females compared to 40% in females in the group without obesity. Statistically significant comorbidities in the obesity group included a Charlson Comorbidity Index score of three and above, diabetes mellitus, hypertension, chronic kidney disease, and sleep apnea. Rates and odds of mortality were not significantly higher in the collective obesity group 39 (10%) vs. 336 (8.5%), p-value 0.62, adjusted odds ratio 1.2, p-value 0.61). The rates and odds of tracheostomy were higher in the obesity group but not statistically significant. Obese patients were also found to have a longer hospitalization. Upon subanalysis of the data, no evidence of racial disparities was found in the care of VAP for both the obese and control groups.
CONCLUSIONS: Obesity was not found to be an independent risk factor for worse outcomes in patients who develop VAP in the intensive care unit.
Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
The invention relates to the technical field of in-vivo implantation intervention composite materials, in particular to a hafnium-based metal organic frame material, a polymer composite material with an X-ray development function and a preparation method thereof. The ligand of the hafnium-based metal organic framework material is terephthalic acid derivative shown in the structure of formula I. The modification of pore channels and ligand functional groups in the hafnium-based metal organic framework material has a promotion effect on X-ray scattering attenuation, and can enhance the X-ray development effect of the composite development material. The interaction between the ligand functional groups and the polymer matrix molecules improves the two-phase interface performance, promotes the uniform dispersion of MOFs filler, and can realize the optimization of the mechanical properties of the composite material without interface modification. The hafnium-based metal organic framework material has excellent water and heat stability and good biocompatibility, so that the selection of a plurality of subsequent processing modes and the application of an in-vivo implantation intervention scene are possible. The preparation method is simple to operate, mild in reaction condition, easy to operate and has industrial implementation prospect.
UNLABELLED: We have demonstrated that SAMHD1 (sterile alpha motif and histidine-aspartic domain HD-containing protein 1) is a restriction factor for the human papillomavirus 16 (HPV16) life cycle. Here, we demonstrate that in HPV-negative cervical cancer C33a cells and human foreskin keratinocytes immortalized by HPV16 (HFK+HPV16), SAMHD1 is recruited to E1-E2 replicating DNA. Homologous recombination (HR) factors are required for HPV16 replication, and viral replication promotes phosphorylation of SAMHD1, which converts it from a dNTPase to an HR factor independent from E6/E7 expression. A SAMHD1 phospho-mimic (SAMHD1 T592D) reduces E1-E2-mediated DNA replication in C33a cells and has enhanced recruitment to the replicating DNA. In HFK+HPV16 cells, SAMHD1 T592D is recruited to the viral DNA and attenuates cellular growth, but does not attenuate growth in isogenic HFK cells immortalized by E6/E7 alone. SAMHD1 T592D also attenuates the development of viral replication foci following keratinocyte differentiation. The results indicated that enhanced SAMHD1 phosphorylation could be therapeutically beneficial in cells with HPV16 replicating genomes. Protein phosphatase 2A (PP2A) can dephosphorylate SAMHD1, and PP2A function can be inhibited by endothall. We demonstrate that endothall reduces E1-E2 replication and promotes SAMHD1 recruitment to E1-E2 replicating DNA, mimicking the SAMHD1 T592D phenotypes. Finally, we demonstrate that in head and neck cancer cell lines with HPV16 episomal genomes, endothall attenuates their growth and promotes recruitment of SAMHD1 to the viral genome. The results suggest that targeting cellular phosphatases has therapeutic potential for the treatment of HPV infections and cancers.
IMPORTANCE: Human papillomaviruses (HPVs) are causative agents in around 5% of all human cancers. The development of anti-viral therapeutics depends upon an increased understanding of the viral life cycle. Here, we demonstrate that HPV16 replication converts sterile alpha motif and histidine-aspartic domain HD-containing protein 1 (SAMHD1) into a homologous recombination (HR) factor via phosphorylation. This phosphorylation promotes recruitment of SAMHD1 to viral DNA to assist with replication. A SAMHD1 mutant that mimics phosphorylation is hyper-recruited to viral DNA and attenuates viral replication. Expression of this mutant in HPV16-immortalized cells attenuates the growth of these cells, but not cells immortalized by the viral oncogenes E6/E7 alone. Finally, we demonstrate that the phosphatase inhibitor endothall promotes hyper-recruitment of endogenous SAMHD1 to HPV16 replicating DNA and can attenuate the growth of both HPV16-immortalized human foreskin keratinocytes (HFKs) and HPV16-positive head and neck cancer cell lines. We propose that phosphatase inhibitors represent a novel tool for combating HPV infections and disease.
OBJECTIVE: Despite considerable improvement in therapeutic approaches to chronic myeloid leukemia (CML) treatment, this malignancy is considered incurable due to resistance. However, investigating the molecular mechanism of CML may give rise to the development of extremely efficient targeted therapies that improve the prognosis of patients. Basic leucine zipper transcription factor ATF-like3 (BATF3), as transcription factor, is considered a key regulator of cellular activities and its function has been evaluated in tumor development and growth in several cancer types. This study aimed to evaluate the potential of the cellular impact of siRNA-mediated downregulation of BATF3 on CML cancer cells through cell proliferation, induction of apoptosis, and cell cycle distribution.
MATERIALS AND METHODS: The transfection of BATF3 siRNA to K562 CML cells was performed by electroporation device. To measure cellular viability and apoptosis, MTT assay and Annexin V/PI staining were carried out, respectively. Also, cell cycle assay and flow cytometry instrument were applied to assess cell cycle distribution of K562 cells. For more validation, mRNA expression of correlated genes was relatively evaluated by quantitative real-time polymerase chain reaction (qRT-PCR).
RESULTS: The data indicated that siRNA-mediated BATF3 inactivating severely promoted the cell apoptosis. Also, the targeted therapy led to high expression of Caspase-3 gene and Bax/Bcl-2 ratio. Silenced BATF3 also induced cell cycle arrest in phase sub-G1 compared to control. Finally, a noticeable decrement was obtained in c-Myc gene expression through suppression of BATF3 in CML cells.
CONCLUSION: The findings of this research illustrated the suppression of BATF3 as an effective targeted therapy strategy for CML.
The invention provides a disinfectant gellant for gynaecology external use and its preparation method, which relates to a pharmaceutical composition for external use to treat gynaecological vaginitis. The disinfectant gellant for gynaecological external use comprises a gel matrix, a penetration enhancer, a bactericide, a surfactant, essence, ethanol and purified water as balance. Each 1000 ml of the disinfectant gellant for gynaecological external use comprises 10% to 12% of gel matrix, penetration enhancer, bactericide, surfactant, essence, ethanol in proportion. The present invention has the advantages that the composite bactericide is added with the penetration enhancer based on chlorhexidine acetate and metronidazole complex formulation. Natural borneol is taken as the penetration enhancer, thereby the invention has double effects of penetrating promotion and sterilization. The invention has the characteristics of wide spectrum, strong sterilization capability and strong nursing capability, as well as the invention employs the gallant for external use.
Facial grimacing is used to quantify spontaneous pain in mice and other mammals, but scoring relies on humans with different levels of proficiency. Here, we developed a cloud-based software platform called PainFace ( http://painface.net ) that uses machine learning to detect 4 facial action units of the mouse grimace scale (orbitals, nose, ears, whiskers) and score facial grimaces of black-coated C57BL/6 male and female mice on a 0 to 8 scale. Platform accuracy was validated in 2 different laboratories, with 3 conditions that evoke grimacing-laparotomy surgery, bilateral hindpaw injection of carrageenan, and intraplantar injection of formalin. PainFace can generate up to 1 grimace score per second from a standard 30 frames/s video, making it possible to quantify facial grimacing over time, and operates at a speed that scales with computing power. By analyzing the frequency distribution of grimace scores, we found that mice spent 7x more time in a "high grimace" state following laparotomy surgery relative to sham surgery controls. Our study shows that PainFace reproducibly quantifies facial grimaces indicative of nonevoked spontaneous pain and enables laboratories to standardize and scale-up facial grimace analyses.
The invention discloses a construction method and application of iTreg cells for knocking down a Sema4D gene, and particularly relates to the technical field of genetic engineering. The method comprises the step of designing a sh-RNA interference sequence to knock down a Sema4D gene in the iTreg cells, wherein the interference sequence is shown as SEQ ID NO. 2. According to the invention, the Sema4D gene in the iTreg cells is knocked down by using the designed sh-RNA through a slow virus infection method, so that the immune suppression function of the iTreg cells is effectively enhanced. The invention can effectively relieve or treat the occurrence and progress of inflammatory diseases by utilizing the Sema4D gene knockdown type iTreg cells. The Sema4D gene knocked down in the iTreg cells can obviously enhance the inhibitory function of the iTreg cells, and provides theoretical basis and experimental data for the treatment or improvement of autoimmune diseases and solid organ transplantation by subsequent Treg cell therapies.
BACKGROUND: The aminoglycoside apramycin has been proposed as a drug candidate for the treatment of critical Gram-negative systemic infections. However, the potential of apramycin in the treatment of drug-resistant bloodstream infections (BSIs) has not yet been assessed.
METHODS: The resistance gene annotations of 40 888 blood-culture isolates were analysed. In vitro profiling of apramycin comprised cell-free translation assays, broth microdilution, and frequency of resistance determination. The efficacy of apramycin was studied in a mouse peritonitis model for a total of nine Escherichia coli and Klebsiella pneumoniae isolates.
RESULTS: Genotypic aminoglycoside resistance was identified in 87.8% of all 6973 carbapenem-resistant Enterobacterales blood-culture isolates, colistin resistance was shown in 46.4% and apramycin in 2.1%. Apramycin activity against methylated ribosomes was > 100-fold higher than that for other aminoglycosides. Frequencies of resistance were < 10-9 at 8 × minimum inhibitory concentration (MIC). Tentative epidemiological cut-offs (TECOFFs) were determined as 8 µg/mL for E. coli and 4 µg/mL for K. pneumoniae. A single dose of 5 to 13 mg/kg resulted in a 1-log colony-forming unit (CFU) reduction in the blood and peritoneum. Two doses of 80 mg/kg resulted in an exposure that resembles the AUC observed for a single 30 mg/kg dose in humans and led to complete eradication of carbapenem- and aminoglycoside-resistant bacteraemia.
CONCLUSION: Encouraging coverage and potent in vivo efficacy against a selection of highly drug-resistant Enterobacterales isolates in the mouse peritonitis model warrants the conduct of clinical studies to validate apramycin as a drug candidate for the prophylaxis and treatment of BSI.
The invention concerns a Ribosome inactibating protein (RIPS) Chinese mainland protein separated from plants which plays a role in anti-AIDS through catalyzing rRNA depurination of prokaryotic and eukaryotic ribosome with highly conserved stem-loop structure at the surface. The invention involves a Tat protein, the basic amino acid enrichment domain of which is protein transduction domain (PTD) and able to carry many exogenous protein directly into cells as protein orientation of cytokines or toxin. The invention involves a fusion protein of Tat and Chinese antiviral protein mutant. Performing deletion mutation to CAP using Quick-mutagenesis site-directed mutagenesis technology: 22 amino acid deletion in N-terminal, 29 amino acid deletion in C-terminal and site-specific mutagenesis: 151KI152/151AA152, 191FN192/191AA192. The recombinant protein of the invention has biological activity of anti-HIV-1 in vitro. It is found that CAP deletion and site-specific mutagenesis in fusion gene can significantly reduce its ability to combine with rRNA (cytotoxicity), however, without influence to its ability of combination of HIV RNA (anti-HIV activity), has more clinical application.